商业化产品组合主要针对消化系统、心血管系统、内分泌系统、神经系统和炎症疾病，这些领域占2023 年中国医药销售总额的25%以上。公司客户主要为国有医药分销公司、药店及零售商。 海西新药向港交所提交上市申请，联席保荐人为华泰国际和招银国际。 公司采用"双轨模式"，涵盖仿制药和在研创新药。已获得14款仿制药的NMPA批准，并有四款在研创新 药，包括一款潜在同类首创的肿瘤药物和一款潜在首款口服wAMD/DME/RVO药物。 ...

Core Viewpoint - Fujian Haixi New Drug Creation Co., Ltd. has submitted its application to the Hong Kong Stock Exchange for listing on the main board, with Huatai International and China Merchants International as joint sponsors. The company is in the commercialization stage and has a diverse product portfolio and pipeline in the rapidly growing therapeutic areas in China [1][2]. Company Overview - Haixi New Drug is a pharmaceutical company that integrates research and development, production, and sales capabilities, with a focus on both generic drugs and innovative drugs in its pipeline [1]. - The company has received approval from the National Medical Products Administration for 14 generic drugs and has established a pipeline of four innovative drugs under development [1]. Product and Market Focus - The company employs a dual-track model, focusing on both generic drugs and innovative drugs. Its generic drugs are characterized by significant technical barriers and market potential, with timely regulatory approvals [1]. - The innovative drug pipeline targets unmet medical needs and has substantial global market potential, including a potential first-in-class oncology drug and an oral drug for treating wAMD/DME/RVO [1]. Financial Performance - As of July 8, 2025, the company's commercialized product portfolio includes generic drugs for digestive, cardiovascular, endocrine, neurological, and inflammatory diseases, which collectively account for over 25% of China's pharmaceutical sales in 2023 [2]. - The company's revenue from the top five customers has shown a decreasing trend from 85.1% in 2022 to 71.7% in the first five months of 2025 [2]. - Revenue figures for the years 2022, 2023, 2024, and the first five months of 2025 are approximately RMB 212 million, RMB 317 million, RMB 467 million, and RMB 249 million, respectively, with corresponding profits of approximately RMB 69 million, RMB 117 million, RMB 136 million, and RMB 90 million [2].

据港交所8月6日披露，福建海西新药创制股份有限公司(以下简称：海西新药)递表港交所主板，华泰国际和招银国 际为其联席保荐人。该公司曾于1月3日向港交所递表。 创新药方面，公司的创新药管线专注于具有未满足医疗需求及巨大全球市场潜力的各种适应症的在研药物，包括 一款潜在属同类首款的在研肿瘤药物、一款潜在用于治疗wAMD/DME/RVO的首款口服药物及另外两款处于临床 前阶段，用于治疗肿瘤及呼吸系统疾病的创新在研药物。 截至2025年7月8日，公司已商业化的产品组合主要包括用于消化系统疾病、心血管系统疾病、内分泌系统疾病、 神经系统疾病及炎症疾病的仿制药；根据灼识咨询的资料，该等治疗领域占2023年中国医药销售总额的25%以 上。 | [編纂]數目 | : [編纂]股H股(視乎[編纂]行使與否而定) | | --- | --- | | [編纂]數目 | .. [編纂]股H股(可予[編纂]) | | [編纂]數目 | : 「編纂]股H股(可予[編纂]及視乎[編纂]行使 | | | 與否而定) | | | 最高[編纂] : 每 股H股[編纂]港 元,另加1.0%經紀佣金、 | | | 證 監 會 交 易 徵 費 0.0 ...

Core Viewpoint - The annual pharmaceutical industry event, CPHI&PMEC China 2025, showcased the comprehensive strength and value advantages of the company's overseas commercialization platform, receiving positive feedback from domestic and international guests [1][2] Group 1: Company Strategy and Development - The company is advancing its "innovation + internationalization" strategy, rapidly progressing in drug research and overseas commercialization, and has established partnerships with several well-known pharmaceutical companies for international collaboration [2] - The company aims to provide superior drugs and comprehensive solutions for global patients by collaborating with outstanding domestic pharmaceutical and medical device enterprises [2] Group 2: Event Highlights - During the CPHI exhibition from June 24 to 26, the company showcased over 20 high-quality drugs, synthetic biology, and medical beauty products, facilitating discussions on its innovative drug pipeline and overseas commercialization with both new and existing clients [2] - The company emphasized its confidence and achievements in overseas business during the forum, highlighting its strategic layout, core advantages in research, production, and sales, as well as its development plans for international markets [2] Group 3: Global Engagement - The company hosted the second "Global Sharing, Co-creating the Future" 2025 International Pharmaceutical High-end Forum, engaging in deep industry dialogue with global clients and partners from 20 countries, including Brazil, Colombia, Saudi Arabia, and Indonesia [2] - The company’s platform for international expansion will continue to be driven by innovation and collaboration, aiming to empower more Chinese pharmaceutical companies to enter international markets [2]